Search Medical Condition
Please enter condition
Please choose location from dropdown

Rennes, France Clinical Trials

A listing of Rennes, France clinical trials actively recruiting patients volunteers.

Found (452) clinical trials

Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy

Global Phase 3, open label long term extension safety study designed to obtain additional safety data for tafamidis meglumine 20 mg and 80 mg (or tafamidis 61 mg where available), and to continue to provide enrolled subjects with tafamidis for up to 60 months, or until subject has access to …

Phase

0.0 miles

Learn More »

Hokusai Study in Pediatric Patients With Confirmed Venous Thromboembolism (VTE)

The objective is to demonstrate the non-inferiority of edoxaban to standard of care (SOC; including low molecular weight heparin (LMWH), vitamin K antagonist (VKA), or synthetic pentasaccharide (SP) Xa inhibitors) in the treatment and secondary prevention of VTE in pediatric subjects with regard to the composite efficacy endpoint (ie, symptomatic …

Phase

0.0 miles

Learn More »

SIRT Followed by CIS-GEM Chemotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma

This clinical study is a prospective, multicenter, randomized, controlled study evaluating SIR-Spheres Y-90 resin microspheres followed by cisplatin-gemcitabine (CIS-GEM) chemotherapy vs. CIS-GEM chemotherapy alone as first-line treatment of patients with unresectable intrahepatic cholangiocarcinoma. Randomized patients will be followed until death, withdrawal of consent, or until end of study.

Phase

0.0 miles

Learn More »

Phase 1 Study to Evaluate the Safety Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma

The purpose of this study is to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of H3B-6527, and to assess the safety, tolerability and pharmacokinetics of H3B-6527.

Phase

0.0 miles

Learn More »

French Registry of First-line Treatment of Acute Promyelocytic Leukemia

Collection of epidemiological data on non-high-risk APL patients aged 70 years: age and sex distribution, medical history, prognostic factors (time to treatment start, severity of coagulopathy at presentation, Performance status). Documentation of clinical and biologic effectiveness of the two first-line treatment approaches available for non-high-risk APL patients. Documentation of Minimal …

Phase N/A

0.0 miles

Learn More »

Transcutaneous Electrical Nerve Stimulation (TENS) for Lower Urinary Tract Disorders in Parkinson's Syndrome

The principal objective is to compare the efficacy of transcutaneous electrical nerve stimulation of the posterior tibial nerve with placebo stimulation, applied 20 minutes daily for 3 months, in Lower Urinary Tract Disorders (LUTD) in patients with Parkinson's disease or multisystem atrophy, evaluated using the PGI-I (Patient Global Impression of …

Phase N/A

0.0 miles

Learn More »

Impact of Fas/FasL in Chemotherapy Response in Epithelial Ovarian Carcinoma

Ovarian carcinoma has poor prognosis and new therapeutic strategies are required. Many patients with ovarian carcinoma showed resistance to chemotherapy. Cleaved FasL is known for induced atypical response when is binding to Fas such as avoiding apoptosis and inducing cell motility.

Phase N/A

0.0 miles

Learn More »

HiFIT Study : Hip Fracture: Iron and Tranexamic Acid

Fractures of the upper end of the femur, called commonly "Hip fractures"are very common, with an incidence of approximately 1.6 million cases per year worldwide. This high incidence is anticipated to grow rapidly in the next decades, driven by population aging. Anemia is very frequent on admission for hip fracture, …

Phase

0.0 miles

Learn More »

First-line Treatment of Ewing Tumours With Primary Extrapulmonary Dissemination in Patients From 2 to 50 Years

Ewing's sarcoma and related tumours (ESFT) are rare tumours, with a peak incidence in the second decade of life. They start most often from bone, and are characterized by a specific translocation involving the so-called EWS gene. The gene rearrangement results in the production of a transcription factor, in the …

Phase

0.0 miles

Learn More »

SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access

SPECTA is a program aiming at establishing a quality assured platform for collecting clinicopathologically annotated biological material, imaging data, as well as patient-reported outcomes from cancer patients to support biospecimen-based translational research and biomarker discovery to improve the understanding of tumor biology and cancer patients care.

Phase N/A

0.0 miles

Learn More »